|

BI1206 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Pembrolizumab 25mg/mL (MK-3475)

Pipeline

Phase 1/2: 1

Top Sponsors

  • BioInvent International AB1

Indications

  • Solid Tumor, Adult1
  • Cancer1

Los Angeles, California1 trial

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

University of California Los Angeles

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.